Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 337 to 348 of 348 entries
Sorted by: Best Match Show Resources per page
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL.

medRxiv : the preprint server for health sciences

Temesgen Z, Burger CD, Baker J, Polk C, Libertin C, Kelley C, Marconi VC, Orenstein R, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD.
PMID: 33972949
medRxiv. 2021 May 05; doi: 10.1101/2021.05.01.21256470.

BACKGROUND: Severe COVID-19 pneumonia results from a hyperinflammatory immune response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of myeloid cells, leading to elevation of downstream inflammatory chemokines (MCP-1, IL-8, IP-10), cytokines (IL-6, IL-1), and other markers...

Cite
Temesgen Z, Burger CD, Baker J, et al. LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. medRxiv. 2021;doi: 10.1101/2021.05.01.21256470.
Temesgen, Z., Burger, C. D., Baker, J., Polk, C., Libertin, C., Kelley, C., Marconi, V. C., Orenstein, R., Durrant, C., Chappell, D., Ahmed, O., Chappell, G., & Badley, A. D. (2021). LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.05.01.21256470
Temesgen, Zelalem, et al. "LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.05.01.21256470
Temesgen Z, Burger CD, Baker J, Polk C, Libertin C, Kelley C, Marconi VC, Orenstein R, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD. LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. medRxiv. 2021 May 05; doi: 10.1101/2021.05.01.21256470. PMID: 33972949; PMCID: PMC8109186.
Copy Download .nbib Format: NLM
Single-shot large field of view Fourier transform holography with a picosecond plasma-based soft X-ray laser.

Optics express

Wang S, Rockwood A, Wang Y, Chao WL, Naulleau P, Song H, Menoni CS, Marconi M, Rocca JJ.
PMID: 33379696
Opt Express. 2020 Nov 23;28(24):35898-35909. doi: 10.1364/OE.409815.

It is challenging to obtain nanoscale resolution images in a single ultrafast shot because a large number of photons, greater than 10

Cite
Wang S, Rockwood A, Wang Y, et al. Single-shot large field of view Fourier transform holography with a picosecond plasma-based soft X-ray laser. Opt Express. 2020;28(24):35898-35909doi: 10.1364/OE.409815.
Wang, S., Rockwood, A., Wang, Y., Chao, W. L., Naulleau, P., Song, H., Menoni, C. S., Marconi, M., & Rocca, J. J. (2020). Single-shot large field of view Fourier transform holography with a picosecond plasma-based soft X-ray laser. Optics express, 28(24), 35898-35909. https://doi.org/10.1364/OE.409815
Wang, Shoujun, et al. "Single-shot large field of view Fourier transform holography with a picosecond plasma-based soft X-ray laser." Optics express vol. 28,24 (2020): 35898-35909. doi: https://doi.org/10.1364/OE.409815
Wang S, Rockwood A, Wang Y, Chao WL, Naulleau P, Song H, Menoni CS, Marconi M, Rocca JJ. Single-shot large field of view Fourier transform holography with a picosecond plasma-based soft X-ray laser. Opt Express. 2020 Nov 23;28(24):35898-35909. doi: 10.1364/OE.409815. PMID: 33379696.
Copy Download .nbib Format: NLM
Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs.

Vaccine: X

Marconi RT, Honsberger N, Teresa Winkler M, Sobell N, King VL, Wappel S, Hoevers J, Xu Z, Millership J.
PMID: 33336186
Vaccine X. 2020 Oct 22;6:100080. doi: 10.1016/j.jvacx.2020.100080. eCollection 2020 Dec 11.

Here we report the results of a large-scale pre-license safety study in which two serials of VANGUARD®crLyme, a vaccine for canine Lyme disease, were tested in its target population (dogs) under the conditions of its intended use. Six-hundred and...

Cite
Marconi RT, Honsberger N, Teresa Winkler M, et al. Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs. Vaccine X. 2020;6:100080doi: 10.1016/j.jvacx.2020.100080.
Marconi, R. T., Honsberger, N., Teresa Winkler, M., Sobell, N., King, V. L., Wappel, S., Hoevers, J., Xu, Z., & Millership, J. (2020). Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs. Vaccine: X, 6100080. https://doi.org/10.1016/j.jvacx.2020.100080
Marconi, Richard T, et al. "Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs." Vaccine: X vol. 6 (2020): 100080. doi: https://doi.org/10.1016/j.jvacx.2020.100080
Marconi RT, Honsberger N, Teresa Winkler M, Sobell N, King VL, Wappel S, Hoevers J, Xu Z, Millership J. Field safety study of VANGUARD®crLyme: A vaccine for the prevention of Lyme disease in dogs. Vaccine X. 2020 Oct 22;6:100080. doi: 10.1016/j.jvacx.2020.100080. eCollection 2020 Dec 11. PMID: 33336186; PMCID: PMC7733143.
Copy Download .nbib Format: NLM
Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.

AIDS (London, England)

Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, Lima VD, Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD.
PMID: 34934020
AIDS. 2022 Feb 01;36(2):277-286. doi: 10.1097/QAD.0000000000003069.

BACKGROUND: Integrase strand transfer inhibitor (InSTI)-based regimens have been recommended as first-line antiretroviral therapy (ART) for adults with HIV. But data on long-term effects of InSTI-based regimens on virologic outcomes remain limited. Here we examined whether InSTI improved long-term...

Cite
Lu H, Cole SR, Westreich D, et al. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. AIDS. 2022;36(2):277-286doi: 10.1097/QAD.0000000000003069.
Lu, H., Cole, S. R., Westreich, D., Hudgens, M. G., Adimora, A. A., Althoff, K. N., Silverberg, M. J., Buchacz, K., Li, J., Edwards, J. K., Rebeiro, P. F., Lima, V. D., Marconi, V. C., Sterling, T. R., Horberg, M. A., Gill, M. J., Kitahata, M. M., Eron, J. J., Moore, R. D. (2022). Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. AIDS (London, England), 36(2), 277-286. https://doi.org/10.1097/QAD.0000000000003069
Lu, Haidong, et al. "Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy." AIDS (London, England) vol. 36,2 (2022): 277-286. doi: https://doi.org/10.1097/QAD.0000000000003069
Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, Lima VD, Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. AIDS. 2022 Feb 01;36(2):277-286. doi: 10.1097/QAD.0000000000003069. PMID: 34934020.
Copy Download .nbib Format: NLM
Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial.

Annals of internal medicine

Siedner MJ, Moosa MS, McCluskey S, Gilbert RF, Pillay S, Aturinda I, Ard K, Muyindike W, Musinguzi N, Masette G, Pillay M, Moodley P, Brijkumar J, Rautenberg T, George G, Gandhi RT, Johnson BA, Sunpath H, Bwana MB, Marconi VC.
PMID: 34698502
Ann Intern Med. 2021 Dec;174(12):1683-1692. doi: 10.7326/M21-2229. Epub 2021 Oct 26.

BACKGROUND: Virologic failure in HIV predicts the development of drug resistance and mortality. Genotypic resistance testing (GRT), which is the standard of care after virologic failure in high-income settings, is rarely implemented in sub-Saharan Africa.OBJECTIVE: To estimate the effectiveness...

Cite
Siedner MJ, Moosa MS, McCluskey S, et al. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Ann Intern Med. 2021;174(12):1683-1692doi: 10.7326/M21-2229.
Siedner, M. J., Moosa, M. S., McCluskey, S., Gilbert, R. F., Pillay, S., Aturinda, I., Ard, K., Muyindike, W., Musinguzi, N., Masette, G., Pillay, M., Moodley, P., Brijkumar, J., Rautenberg, T., George, G., Gandhi, R. T., Johnson, B. A., Sunpath, H., Bwana, M. B., & Marconi, V. C. (2021). Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Annals of internal medicine, 174(12), 1683-1692. https://doi.org/10.7326/M21-2229
Siedner, Mark J, et al. "Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial." Annals of internal medicine vol. 174,12 (2021): 1683-1692. doi: https://doi.org/10.7326/M21-2229
Siedner MJ, Moosa MS, McCluskey S, Gilbert RF, Pillay S, Aturinda I, Ard K, Muyindike W, Musinguzi N, Masette G, Pillay M, Moodley P, Brijkumar J, Rautenberg T, George G, Gandhi RT, Johnson BA, Sunpath H, Bwana MB, Marconi VC. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Ann Intern Med. 2021 Dec;174(12):1683-1692. doi: 10.7326/M21-2229. Epub 2021 Oct 26. PMID: 34698502; PMCID: PMC8688215.
Copy Download .nbib Format: NLM
Weight gain stopping/switch rules for antiretroviral clinical trials.

AIDS (London, England)

Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S.
PMID: 34848585
AIDS. 2021 Dec 15;35:S183-S188. doi: 10.1097/QAD.0000000000003092.

Obesity develops in a substantial number of people initiating and maintaining modern antiretroviral therapy. The comorbidities associated with obesity make significant weight gain and metabolic changes a major consideration in clinical trials studying different regimens' potency and safety. It...

Cite
Venter WDF, Sokhela S, Calmy A, et al. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021;35:S183-S188doi: 10.1097/QAD.0000000000003092.
Venter, W. D. F., Sokhela, S., Calmy, A., Mkhondwane, L., Bosch, B., Chandiwana, N., Hill, A., Sekwese, K., Mashabane, N., Pozniak, A., Khoo, S., Ali, M., Delaporte, E., Lalla-Edwards, S., Clayden, P., Marconi, V. C., Siedner, M. J., Boffito, M., Serenata, C., Carman, M., & Collins, S. (2021). Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS (London, England), 35S183-S188. https://doi.org/10.1097/QAD.0000000000003092
Venter, W D Francois, et al. "Weight gain stopping/switch rules for antiretroviral clinical trials." AIDS (London, England) vol. 35 (2021): S183-S188. doi: https://doi.org/10.1097/QAD.0000000000003092
Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021 Dec 15;35:S183-S188. doi: 10.1097/QAD.0000000000003092. PMID: 34848585; PMCID: PMC8694575.
Copy Download .nbib Format: NLM
Preservative systems containing essential oils in cosmetic products.

International journal of cosmetic science

Maccioni AM, Anchisi C, Sanna A, Sardu C, Dessì S.
PMID: 18498495
Int J Cosmet Sci. 2002 Feb;24(1):53-9. doi: 10.1046/j.0412-5463.2001.00113.x.

The aim of this study was to evaluate the antimicrobial activity of selected essential oils (Laurus nobilis, Eucalyptus globulus and Salvia officinalis), both alone and in combination, in cosmetic preparations characterized by an increasing risk of microbial contamination, i.e....

Cite
Maccioni AM, Anchisi C, Sanna A, et al. Preservative systems containing essential oils in cosmetic products. Int J Cosmet Sci. 2002;24(1):53-9doi: 10.1046/j.0412-5463.2001.00113.x.
Maccioni, A. M., Anchisi, C., Sanna, A., Sardu, C., & Dessì, S. (2002). Preservative systems containing essential oils in cosmetic products. International journal of cosmetic science, 24(1), 53-9. https://doi.org/10.1046/j.0412-5463.2001.00113.x
Maccioni, A M, et al. "Preservative systems containing essential oils in cosmetic products." International journal of cosmetic science vol. 24,1 (2002): 53-9. doi: https://doi.org/10.1046/j.0412-5463.2001.00113.x
Maccioni AM, Anchisi C, Sanna A, Sardu C, Dessì S. Preservative systems containing essential oils in cosmetic products. Int J Cosmet Sci. 2002 Feb;24(1):53-9. doi: 10.1046/j.0412-5463.2001.00113.x. PMID: 18498495.
Copy Download .nbib Format: NLM
Erbium emission in MOS light emitting devices: from energy transfer to direct impact excitation.

Nanotechnology

Ramíırez JM, Ferrarese Lupi F, Jambois O, Berencén Y, Navarro-Urrios D, Anopchenko A, Marconi A, Prtljaga N, Tengattini A, Pavesi L, Colonna JP, Fedeli JM, Garrido B.
PMID: 22414783
Nanotechnology. 2012 Mar 30;23(12):125203. doi: 10.1088/0957-4484/23/12/125203.

The electroluminescence (EL) at 1.54 μm of metal–oxide–semiconductor (MOS) devices withEr3C ions embedded in the silicon-rich silicon oxide (SRSO) layer has been investigated under different polarization conditions and compared with that of erbium doped SiO2 layers. EL time-resolved measurements...

Cite
Ramíırez JM, Ferrarese Lupi F, Jambois O, et al. Erbium emission in MOS light emitting devices: from energy transfer to direct impact excitation. Nanotechnology. 2012;23(12):125203doi: 10.1088/0957-4484/23/12/125203.
Ramíırez, J. M., Ferrarese Lupi, F., Jambois, O., Berencén, Y., Navarro-Urrios, D., Anopchenko, A., Marconi, A., Prtljaga, N., Tengattini, A., Pavesi, L., Colonna, J. P., Fedeli, J. M., & Garrido, B. (2012). Erbium emission in MOS light emitting devices: from energy transfer to direct impact excitation. Nanotechnology, 23(12), 125203. https://doi.org/10.1088/0957-4484/23/12/125203
Ramíırez, J M, et al. "Erbium emission in MOS light emitting devices: from energy transfer to direct impact excitation." Nanotechnology vol. 23,12 (2012): 125203. doi: https://doi.org/10.1088/0957-4484/23/12/125203
Ramíırez JM, Ferrarese Lupi F, Jambois O, Berencén Y, Navarro-Urrios D, Anopchenko A, Marconi A, Prtljaga N, Tengattini A, Pavesi L, Colonna JP, Fedeli JM, Garrido B. Erbium emission in MOS light emitting devices: from energy transfer to direct impact excitation. Nanotechnology. 2012 Mar 30;23(12):125203. doi: 10.1088/0957-4484/23/12/125203. PMID: 22414783.
Copy Download .nbib Format: NLM
Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers.

Cancer cell international

Turk CM, Fagan-Solis KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi SA, Otis CN, Crisi GM, Anderton DL, Kilimann MW, Arcaro KF.
PMID: 22574838
Cancer Cell Int. 2012 May 10;12(1):17. doi: 10.1186/1475-2867-12-17.

BACKGROUND: Paralemmin-1 is a phosphoprotein lipid-anchored to the cytoplasmic face of membranes where it functions in membrane dynamics, maintenance of cell shape, and process formation. Expression of paralemmin-1 and its major splice variant (Δ exon 8) as well as...

Cite
Turk CM, Fagan-Solis KD, Williams KE, et al. Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell Int. 2012;12(1):17doi: 10.1186/1475-2867-12-17.
Turk, C. M., Fagan-Solis, K. D., Williams, K. E., Gozgit, J. M., Smith-Schneider, S., Marconi, S. A., Otis, C. N., Crisi, G. M., Anderton, D. L., Kilimann, M. W., & Arcaro, K. F. (2012). Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer cell international, 12(1), 17. https://doi.org/10.1186/1475-2867-12-17
Turk, Casey M, et al. "Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers." Cancer cell international vol. 12,1 (2012): 17. doi: https://doi.org/10.1186/1475-2867-12-17
Turk CM, Fagan-Solis KD, Williams KE, Gozgit JM, Smith-Schneider S, Marconi SA, Otis CN, Crisi GM, Anderton DL, Kilimann MW, Arcaro KF. Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers. Cancer Cell Int. 2012 May 10;12(1):17. doi: 10.1186/1475-2867-12-17. PMID: 22574838; PMCID: PMC3503693.
Copy Download .nbib Format: NLM
Cognitively-Based Compassion Training for HIV Immune Non-responders - An Attention-Placebo Randomized Controlled Trial.

Journal of acquired immune deficiency syndromes (1999)

Titanji BK, Tejani M, Farber EW, Mehta CC, Pace TW, Meagley K, Gavegnano C, Harrison T, Kokubun CW, Negi SD, Schinazi RF, Marconi VC.
PMID: 34879006
J Acquir Immune Defic Syndr. 2021 Dec 07; doi: 10.1097/QAI.0000000000002874. Epub 2021 Dec 07.

OBJECTIVE: Chronic inflammation is associated with increased morbidity and mortality for people with HIV (PWH). Psychological stress is an important contributor to this chronic inflammation. We hypothesized that a Cognitively-Based Compassion Training (CBCT) approach could reduce inflammation and psychological...

Cite
Titanji BK, Tejani M, Farber EW, et al. Cognitively-Based Compassion Training for HIV Immune Non-responders - An Attention-Placebo Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2021;doi: 10.1097/QAI.0000000000002874.
Titanji, B. K., Tejani, M., Farber, E. W., Mehta, C. C., Pace, T. W., Meagley, K., Gavegnano, C., Harrison, T., Kokubun, C. W., Negi, S. D., Schinazi, R. F., & Marconi, V. C. (2021). Cognitively-Based Compassion Training for HIV Immune Non-responders - An Attention-Placebo Randomized Controlled Trial. Journal of acquired immune deficiency syndromes (1999), . https://doi.org/10.1097/QAI.0000000000002874
Titanji, Boghuma K, et al. "Cognitively-Based Compassion Training for HIV Immune Non-responders - An Attention-Placebo Randomized Controlled Trial." Journal of acquired immune deficiency syndromes (1999) vol. (2021). doi: https://doi.org/10.1097/QAI.0000000000002874
Titanji BK, Tejani M, Farber EW, Mehta CC, Pace TW, Meagley K, Gavegnano C, Harrison T, Kokubun CW, Negi SD, Schinazi RF, Marconi VC. Cognitively-Based Compassion Training for HIV Immune Non-responders - An Attention-Placebo Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2021 Dec 07; doi: 10.1097/QAI.0000000000002874. Epub 2021 Dec 07. PMID: 34879006.
Copy Download .nbib Format: NLM
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression.

Cancer research

Saltari A, Dzung A, Quadri M, Tiso N, Facchinello N, Hernández-Barranco A, Garcia-Silva S, Nogués L, Stoffel CI, Cheng PF, Turko P, Eichhoff OM, Truzzi F, Marconi A, Pincelli C, Peinado H, Dummer R, Levesque MP.
PMID: 34645608
Cancer Res. 2021 Dec 01;81(23):6044-6057. doi: 10.1158/0008-5472.CAN-21-0117. Epub 2021 Oct 13.

CD271 (NGFR) is a neurotrophin receptor that belongs to the tumor necrosis receptor (TNFR) family. Upon ligand binding, CD271 can mediate either survival or cell death. Although the role of CD271 as a marker of tumor-initiating cells is still...

Cite
Saltari A, Dzung A, Quadri M, et al. Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. Cancer Res. 2021;81(23):6044-6057doi: 10.1158/0008-5472.CAN-21-0117.
Saltari, A., Dzung, A., Quadri, M., Tiso, N., Facchinello, N., Hernández-Barranco, A., Garcia-Silva, S., Nogués, L., Stoffel, C. I., Cheng, P. F., Turko, P., Eichhoff, O. M., Truzzi, F., Marconi, A., Pincelli, C., Peinado, H., Dummer, R., & Levesque, M. P. (2021). Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. Cancer research, 81(23), 6044-6057. https://doi.org/10.1158/0008-5472.CAN-21-0117
Saltari, Annalisa, et al. "Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression." Cancer research vol. 81,23 (2021): 6044-6057. doi: https://doi.org/10.1158/0008-5472.CAN-21-0117
Saltari A, Dzung A, Quadri M, Tiso N, Facchinello N, Hernández-Barranco A, Garcia-Silva S, Nogués L, Stoffel CI, Cheng PF, Turko P, Eichhoff OM, Truzzi F, Marconi A, Pincelli C, Peinado H, Dummer R, Levesque MP. Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. Cancer Res. 2021 Dec 01;81(23):6044-6057. doi: 10.1158/0008-5472.CAN-21-0117. Epub 2021 Oct 13. PMID: 34645608.
Copy Download .nbib Format: NLM
"Add-Ons" for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics' Websites?.

Reproductive sciences (Thousand Oaks, Calif.)

Galiano V, Orvieto R, Machtinger R, Nahum R, Garzia E, Sulpizio P, Marconi AM, Seidman D.
PMID: 33939166
Reprod Sci. 2021 Dec;28(12):3466-3472. doi: 10.1007/s43032-021-00601-7. Epub 2021 Apr 30.

"Add-on" procedures are actively promoted on some fertility clinic websites as proven means to improve IVF success rates, especially for couples with repeated implantation/IVF failures. However, the actual contribution of these interventions to live birth rates remains inconclusive. At...

Cite
Galiano V, Orvieto R, Machtinger R, et al. "Add-Ons" for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics' Websites?. Reprod Sci. 2021;28(12):3466-3472doi: 10.1007/s43032-021-00601-7.
Galiano, V., Orvieto, R., Machtinger, R., Nahum, R., Garzia, E., Sulpizio, P., Marconi, A. M., & Seidman, D. (2021). "Add-Ons" for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics' Websites?. Reproductive sciences (Thousand Oaks, Calif.), 28(12), 3466-3472. https://doi.org/10.1007/s43032-021-00601-7
Galiano, Valentina, et al. ""Add-Ons" for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics' Websites?." Reproductive sciences (Thousand Oaks, Calif.) vol. 28,12 (2021): 3466-3472. doi: https://doi.org/10.1007/s43032-021-00601-7
Galiano V, Orvieto R, Machtinger R, Nahum R, Garzia E, Sulpizio P, Marconi AM, Seidman D. "Add-Ons" for Assisted Reproductive Technology: Do Patients Get Honest Information from Fertility Clinics' Websites?. Reprod Sci. 2021 Dec;28(12):3466-3472. doi: 10.1007/s43032-021-00601-7. Epub 2021 Apr 30. PMID: 33939166.
Copy Download .nbib Format: NLM
Showing 337 to 348 of 348 entries